Not known: hemorrhagic disorder.
Immune system disorders
Not known: anaphylactoid reaction, hypersensitivity
Not known: agitation, anxiety, confusion, hallucination
Nervous system disorders
Not known: ataxia, balance impaired, epilepsy aggravated, headache, insomnia
Ear and labyrinth disorders
Not known: vertigo
Not known: abdominal pain, abdominal pain upper, diarrhea, nausea, vomiting
Skin and subcutaneous tissue disorders
Not known: angioneurotic edema, dermatitis, pruritus, urticaria
General disorders and administration site conditions
Common: weight increased
Due to the effect of piracetam on platelet aggregation, caution is recommended in patients with severe hemorrhage, patients at risk of bleeding such as gastrointestinal ulcer, patients with underlying disorders of haemostasis, patients with history of haemorrhagic CVA, patients undergoing major surgery including dental surgery, and patients using anticoagulants or platelet antiaggregant drugs including low dose aspirin.
Piracetam is eliminated via kidney and thus care should be taken in cases of renal insufficiency.
For long-term treatment in the elderly, regular evaluation of the creatinine clearance is required to allow dosage adaptation if needed.
Abrupt discontinuation of treatment should be avoided as this may induce myoclonic or generalised seizures in some myoclonic patients.
The standard Piracetam (Cogpex) dose is between 40-100 mg/kg of bodyweight.
The standard Piracetam (Cogpex) dose is between 2 gm-4.8 gm two to three times in a day.